Investor Center Home


Corporate Profile
Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders.

More >>

BLCM (Common Stock)
(US Dollar)
Price$16.05
Change Stock is Down 0.54
(%)Volume (3.25%)361,986
ExchangeNASDAQ
Data as of 12/09/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
DateTitle 
12/05/16Bellicum Presents Clinical Results to Date of BPX-501 Pediatric Program and Provides Regulatory Update at Investor Event During ASH Annual MeetingPrinter Friendly Version
12/05/16Bellicum Pharmaceuticals Announces GoCAR-T and GoTCR Preclinical Presentations at the American Society of Hematology 2016 Annual MeetingPrinter Friendly Version
12/03/16Bellicum Announces Updated Clinical Data from BPX-501 Study in Children with Primary Immune Deficiencies and HemoglobinopathiesPrinter Friendly Version
11/16/16Bellicum Pharmaceuticals Recommended for $16.9 Million Award from the Cancer Prevention and Research Institute of TexasPrinter Friendly Version
More >>
Upcoming Events
There are currently no events scheduled.
Past Events
12/05/16 12:15 p.m. PT
Bellicum ASH Investor & Analyst Lunch
Click here for webcast
12/03/16
through
12/05/16
ASH Presentations on Bellicum Programs
Description: 

BPX-501:

Oral Presentation:Outcome of Children with Primary Immune-Deficiencies (PIDs) Enrolled in a Phase I-II Trial Based on the Infusion of BPX-501 Donor T Cells Genetically Modified with a Novel Suicide Gene (Inducible Caspase 9, iC9) After T-Cell Depleted HLA-Haploidentical Allogeneic Stem Cell Transplantation (Haplo-HSCT)
Abstract Number: 72
Session Name: 732.Clinical Allogeneic Transplantation: Results: Predicting Outcome
Date: Saturday, December 3, 2016
Session Time: 7:30 AM - 9:00 AM PST
Presentation Time: 8:45 AM PST

Poster Presentation: Clinical Outcome and Immune Recovery after Adoptive Infusion of BPX-501 Cells (Donor T Cells Transduced with iC9 Suicide Gene) in Children with Hemoglobinopathies and Diamond-Blackfan Anemia Given a/b T-Cell Depleted HLA-Haploidentical Stem Cell Transplantation (HSCT)
Abstract Number: 2286
Session Name: 732.Clinical Allogeneic Transplantation: Results: Poster I
Date: Saturday, December 3, 2016
Presentation Time: 5:30 PM - 7:30 PM PST

Poster Presentation:T-Cell Depleted HLA-Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (Haplo-HSCT) Followed by Donor Lymphocyte Infusion with T Cells Transduced with the Inducible Caspase 9 (iC9) Suicide Gene in Children with Hematological Malignancies
Abstract Number: 4683
Session Name: 732.Clinical Allogeneic Transplantation: Results: Poster III
Date: Monday, December 5, 2016
Presentation Time: 6:00 PM - 8:00 PM PST

CAR-T Program: (CD123 CARs)

Poster Presentation:Inducible MyD88/CD40 (iMC) Costimulation Provides Ligand-Dependent Tumor Eradication by CD123-Specific Chimeric Antigen Receptor T Cells
Abstract Number: 4551
Session Name: 703.Adoptive Immunotherapy: Poster III
Date: Monday, December 5, 2016
Presentation Time: 6:00 PM – 8:00 PM PST

TCR Program: (PRAME and Bob-1 TCRs)

Poster Presentation: Inducible MyD88/CD40 (iMC) Enhances Proliferation and Survival of Tumor-Specific TCR-Modified T Cells and Improves Anti-Tumor Efficacy in Myeloma
Abstract Number: 4550
Session Name: 703.Adoptive Immunotherapy: Poster III
Date: Monday, December 5, 2016
Presentation Time: 6:00 PM – 8:00 PM PST

More >>
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources